Showing 5,101 - 5,120 results of 30,932 for search '(( 50 ((mean decrease) OR (((nn decrease) OR (a decrease)))) ) OR ( 2 step decrease ))', query time: 0.99s Refine Results
  1. 5101
  2. 5102
  3. 5103
  4. 5104
  5. 5105
  6. 5106
  7. 5107
  8. 5108
  9. 5109
  10. 5110
  11. 5111

    LIN-2 and FRM-3 regulate the synaptic abundance but not surface expression level of AChRs. by Lei Li (29537)

    Published 2022
    “…Representative traces (E, G) and mean current amplitude (F, H) are shown. (I, J) GABA-activated currents were decreased by 50% in <i>lin-2</i><sup><i>null</i></sup> mutants but were unchanged in <i>frm-3</i><sup><i>null</i></sup> mutants. …”
  12. 5112
  13. 5113
  14. 5114

    HK2 regulates mRNA translation in melanoma cells. by Ana Luisa Dian (22258504)

    Published 2025
    “…<p><b>(A)</b> Western blot analysis of HK2, PKM2, GAPDH, LDHB, and the ribosomal protein S6 in fractions (horizontal axes) obtained by sucrose-gradient (10%–50%) ultracentrifugation of lysates from A375 cells. …”
  15. 5115
  16. 5116
  17. 5117
  18. 5118
  19. 5119

    image2_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

    Published 2020
    “…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”
  20. 5120

    presentation1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.pptx by Xin Zhi (1829224)

    Published 2021
    “…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”